<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861246</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08-006C</org_study_id>
    <nct_id>NCT04861246</nct_id>
  </id_info>
  <brief_title>Evaluation of Laser Treatment for Benign Pigmented Lesions by Non-invasive, Cellular Resolution Optical Coherence Tomography</brief_title>
  <official_title>Evaluation of Laser Treatment for Benign Pigmented Lesions by Non-invasive, Cellular Resolution Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apollo Medical Optics, Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, with the maturity of laser technology, laser therapy is one of the popular&#xD;
      options for the treatment of pigment diseases. The absorption spectrum of melanin ranges from&#xD;
      300 to 1,000 nm. In past studies, the 532 nm Q-switched Nd:YAG laser is effective for the&#xD;
      treatment of superficial melanin. But there are still some side effects in laser treatment,&#xD;
      such as post-inflammation pigmentation (PIH), depigmentation, skin redness, etc., and PIH is&#xD;
      particularly likely to occur on darker skin. However, there is still no good evidence as to&#xD;
      what factors or laser treatments can cause PIH.&#xD;
&#xD;
      Therefore, in this study, we will use ApolloVue® S100 Image System (ApolloVue® S100 Image&#xD;
      System is a medical device class II) to scan before and after skin of laser treatment to&#xD;
      observe the changes in the skin condition. By observing and analyzing these changes, as a&#xD;
      evaluation of predictors or prognostic factors after laser treatment and whether PIH will&#xD;
      occur.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Static Physician's Global Assessment (PGA)</measure>
    <time_frame>one and a half years</time_frame>
    <description>Static PGA is often used to evaluate disease severity of psoriasis. In recent years, this evaluation index has also been applied to pigmented diseases, such as solar lentigo, melasma, and vitiligo. In this trial, Static PGA divides the severity of pigmented diseases into 0~8.&#xD;
0: Extremely lighter than pigment of surrounding skin (completely depigmented)&#xD;
markedly lighter than pigment of surrounding skin&#xD;
moderately lighter than pigment of surrounding skin&#xD;
slightly lighter than pigment of surrounding skin&#xD;
equal with pigment of surrounding skin&#xD;
slightly darker than pigment of surrounding skin&#xD;
moderately darker than pigment of surrounding skin&#xD;
markedly darker than pigment of surrounding skin&#xD;
extremely darker than pigment of surrounding skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic Physician's Global Assessment (PGA)</measure>
    <time_frame>one and a half years</time_frame>
    <description>Dynamic PGA is often used to evaluate the degree of improvement after treatment of the disease. In this trial, Dynamic PGA evaluates the degree of improvement after comparing with the state before treatment (baseline). The degree of improvement is divided into 0~5.&#xD;
0: completely cleared of undesired pigment; no evidence of cosmetic deficit remaining; 100% improvement&#xD;
significant clearance of undesired pigment; slight evidence of cosmetic deficit remaining; about 75% improvement&#xD;
moderate clearance of undesired pigment; moderate evidence of cosmetic deficit remaining; about 50% improvement&#xD;
slight clearance of undesired pigment; marked evidence of cosmetic deficit remaining; about 25% improvement&#xD;
no change in cosmetic appearance from baseline&#xD;
cosmetic appearance worse than at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>one and a half years</time_frame>
    <description>During the two follow-up visits after treatment, subjects will evaluate their satisfaction after treatment. In this trial, this evaluation form will be divided into 0 to 5 points according to the degree of improvement.&#xD;
0: completely cleared of undesired pigment; no evidence of cosmetic deficit remaining; 100% improvement&#xD;
significant clearance of undesired pigment; slight evidence of cosmetic deficit remaining; about 75% improvement&#xD;
moderate clearance of undesired pigment; moderate evidence of cosmetic deficit remaining; about 50% improvement&#xD;
slight clearance of undesired pigment; marked evidence of cosmetic deficit remaining; about 25% improvement&#xD;
no change in cosmetic appearance from baseline&#xD;
cosmetic appearance worse than at baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Benign Pigmented Lesions</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermal pigmented lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ApolloVue® S100 Image System</intervention_name>
    <description>The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISIA®</intervention_name>
    <description>The device is skin analysis system and will be used to obtain before and after images of laser treatment.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≧ 20&#xD;
&#xD;
          -  Both gender are accepted&#xD;
&#xD;
          -  Subject with at least three epidermal pigmented lesions on face&#xD;
&#xD;
          -  The diameter of solar lentigo are ≦ 0.5*0.5 cm2&#xD;
&#xD;
          -  Fitzpatrick skin Type III or IV&#xD;
&#xD;
          -  Subject having lentigos graded 5 or more on the severity grading scale&#xD;
&#xD;
          -  Clinically and dermoscopic confirmed epidermal pigmented lesions on the face which&#xD;
             were no treated in the last 12 months&#xD;
&#xD;
          -  Accepts not to expose the face to sunlight or artificial UV rays during the study&#xD;
&#xD;
          -  Is willing to comply with all requirements of the study including being photographed,&#xD;
             following post treatment care and attending all treatment and follow up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous use of other topical skin lightening&#xD;
&#xD;
          -  Refuses to comply the requirements during the study&#xD;
&#xD;
          -  Pregnant woman or woman wishing to be pregnant during the study, or during&#xD;
             breastfeeding period&#xD;
&#xD;
          -  Has any condition which, in the investigator's opinion, would make it unsafe for&#xD;
             participating in this research study&#xD;
&#xD;
          -  Has systemic skin disorders or infections&#xD;
&#xD;
          -  Is enrolled or accepted other investigational drug or medical device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng-Yuan Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsin Cheng, CRA</last_name>
    <phone>+886-2-87523198</phone>
    <phone_ext>103</phone_ext>
    <email>hsin@mdamo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei city</city>
        <state>Beitou District</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Cheng-Yuan Li, M.D.</last_name>
      <phone>+886-976-731-763</phone>
      <email>cylee38@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Ding-Dar Lee, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chiang Chen, M.D., Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun-Ting Chang, M.D., Ph. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013 Oct;169 Suppl 3:41-56. doi: 10.1111/bjd.12536. Review.</citation>
    <PMID>24098900</PMID>
  </reference>
  <reference>
    <citation>Vachiramon V, Panmanee W, Techapichetvanich T, Chanprapaph K. Comparison of Q-switched Nd: YAG laser and fractional carbon dioxide laser for the treatment of solar lentigines in Asians. Lasers Surg Med. 2016 Apr;48(4):354-9. doi: 10.1002/lsm.22472. Epub 2016 Jan 12.</citation>
    <PMID>27096729</PMID>
  </reference>
  <reference>
    <citation>Wang CC, Sue YM, Yang CH, Chen CK. A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomized, physician-blinded, split-face comparative trial. J Am Acad Dermatol. 2006 May;54(5):804-10.</citation>
    <PMID>16635661</PMID>
  </reference>
  <reference>
    <citation>Kang HJ, Na JI, Lee JH, Roh MR, Ko JY, Chang SE. Postinflammatory hyperpigmentation associated with treatment of solar lentigines using a Q-Switched 532-nm Nd: YAG laser: a multicenter survey. J Dermatolog Treat. 2017 Aug;28(5):447-451. doi: 10.1080/09546634.2016.1254330. Epub 2016 Nov 15.</citation>
    <PMID>27786580</PMID>
  </reference>
  <reference>
    <citation>Hwang CY, Chen CC. Serial change in laser-induced optical breakdown by 1064-nm Nd:YAG picosecond laser. Photodermatol Photoimmunol Photomed. 2020 Jan;36(1):63-64. doi: 10.1111/phpp.12505. Epub 2019 Aug 29.</citation>
    <PMID>31396986</PMID>
  </reference>
  <reference>
    <citation>Wang YJ, Huang YK, Wang JY, Wu YH. In vivo characterization of large cell acanthoma by cellular resolution optical coherent tomography. Photodiagnosis Photodyn Ther. 2019 Jun;26:199-202. doi: 10.1016/j.pdpdt.2019.03.020. Epub 2019 Mar 30.</citation>
    <PMID>30940575</PMID>
  </reference>
  <reference>
    <citation>Farhi D, Falissard B, Dupuy A. Global assessment of psoriasis severity and change from photographs: a valid and consistent method. J Invest Dermatol. 2008 Sep;128(9):2198-203. doi: 10.1038/jid.2008.68. Epub 2008 Apr 17.</citation>
    <PMID>18418412</PMID>
  </reference>
  <reference>
    <citation>Arginelli F, Greco M, Ciardo S, Josse G, Rossi AB, Le Digabel J, Questel E, Chester J, Pellacani G. Efficacy of D-pigment dermocosmetic lightening product for solar lentigo lesions of the hand: A randomized controlled trial. PLoS One. 2019 May 1;14(5):e0214714. doi: 10.1371/journal.pone.0214714. eCollection 2019.</citation>
    <PMID>31042723</PMID>
  </reference>
  <reference>
    <citation>Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006 Dec;156 Suppl 1:21-8.</citation>
    <PMID>17176301</PMID>
  </reference>
  <reference>
    <citation>van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R; participants of the Rome International VGICC /VIS Workshop. Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell Melanoma Res. 2019 Sep;32(5):728-733. doi: 10.1111/pcmr.12784. Epub 2019 May 9.</citation>
    <PMID>30945409</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Optical Coherence Tomograohy</keyword>
  <keyword>Non-invasive image system</keyword>
  <keyword>Cellular level resolution</keyword>
  <keyword>Full-Field OCT</keyword>
  <keyword>Hyperpigmentation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

